Form 8-K - Current report:
SEC Accession No. 0001193125-24-207854
Filing Date
2024-08-27
Accepted
2024-08-27 17:21:52
Documents
14
Period of Report
2024-08-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d884075d8k.htm   iXBRL 8-K 30380
2 EX-10.1 d884075dex101.htm EX-10.1 117390
  Complete submission text file 0001193125-24-207854.txt   291348

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA elym-20240823.xsd EX-101.SCH 2839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elym-20240823_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elym-20240823_pre.xml EX-101.PRE 11251
16 EXTRACTED XBRL INSTANCE DOCUMENT d884075d8k_htm.xml XML 3651
Mailing Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808
Business Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808 877-354-3689
Eliem Therapeutics, Inc. (Filer) CIK: 0001768446 (see all company filings)

EIN.: 832273741 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40708 | Film No.: 241250082
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)